Evidence check: CYP2D6 in the context of stress

The provided context contains no information about CYP2D6 in relation to stress. CYP2D6 is a phase I drug-metabolizing enzyme, primarily known for breaking down many medications (e.g., antidepressants, beta-blockers, antipsychotics). Some studies suggest that CYP2D6 polymorphisms may influence stress regulation through altered neurotransmitter levels (serotonin, dopamine). However, the evidence is mostly mechanistic and insufficient for clinical recommendations. Without specific sources from the given context, the evidence must be rated as unclear. Consumers should not rely solely on CYP2D6 genetic tests to guide stress management strategies.